A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)
Phase
3Span
283 weeksSponsor
UCB Biopharma SRLKoriyama
Recruiting
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Phase
3Span
222 weeksSponsor
SanofiKoriyama, Fukushima
Recruiting
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Phase
3Span
178 weeksSponsor
SanofiKoriyama, Fukushima
Recruiting
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
Phase
2Span
104 weeksSponsor
Kyowa Kirin Co., Ltd.Koriyama, Fukushima
Recruiting
Koriyama, Fukushima
Recruiting
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Phase
3Span
217 weeksSponsor
Karuna TherapeuticsKoriyama, Fukushima
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Phase
3Span
108 weeksSponsor
Karuna TherapeuticsKoriyama, Fukushima
Recruiting
1-7 of 7